What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to determine the pharmacodynamics of cisplatin following three different treatment procedures for intrahepatic arterial infusion therapy for hepatocellular carcinoma (HCC). Methods: We divided 13 HCC patients into the following three groups: group A,lone injection of cisplatin (n=3); group B, combined injection of cisplatin and lipiodol, with embolization using small gelatin cubes (GCs) (n=5); and group C, injection of suspended lipiodol with cisplatin powder, with embolization using small GCs (n=5). In each group, the free cisplatin concentration in the hepatic vein was measured at 0, 5, 10, and 30 minutes. Results: The mean free cisplatin concentrations were as follows. For group A, the mean was 48.58 μg/mL at 0 minute,7.31 μg/mL at 5 minutes, 5.70 μg/mL at 10 minutes, and 7.15 μg/mL at 30 minutes. For the same time points, for group B, the concentrations were 8.66, 4.23, 3.22, and 1.65μg/mL, respectively, and for group C, the concentrations were 4.81, 2.61, 2.52, and 1.75 μg/mL, respectively. The mean area under the curve (AUC)0-infinity for the free cisplatin concentration was 7.80 in group A, 2.48 in group B, and 2.27in group C. The AUC0-infinity for the free cisplatin concentration gradually decreased, from group A to group C. Conclusions:These results indicate that the combination of lipiodol and small GCs may be useful for delaying cisplatin drainage from the liver.
Abstract
Background/Aims: The aim of this study was to determine the pharmacodynamics of cisplatin following three different treatment procedures for intrahepatic arterial infusion therapy for hepatocellular carcinoma (HCC). Methods: We divided 13 HCC patients into the following three groups: group A,lone injection of cisplatin (n=3); group B, combined injection of cisplatin and lipiodol, with embolization using small gelatin cubes (GCs) (n=5); and group C, injection of suspended lipiodol with cisplatin powder, with embolization using small GCs (n=5). In each group, the free cisplatin concentration in the hepatic vein was measured at 0, 5, 10, and 30 minutes. Results: The mean free cisplatin concentrations were as follows. For group A, the mean was 48.58 μg/mL at 0 minute,7.31 μg/mL at 5 minutes, 5.70 μg/mL at 10 minutes, and 7.15 μg/mL at 30 minutes. For the same time points, for group B, the concentrations were 8.66, 4.23, 3.22, and 1.65μg/mL, respectively, and for group C, the concentrations were 4.81, 2.61, 2.52, and 1.75 μg/mL, respectively. The mean area under the curve (AUC)0-infinity for the free cisplatin concentration was 7.80 in group A, 2.48 in group B, and 2.27in group C. The AUC0-infinity for the free cisplatin concentration gradually decreased, from group A to group C. Conclusions:These results indicate that the combination of lipiodol and small GCs may be useful for delaying cisplatin drainage from the liver.
참고문헌 (30)
- The Liver Cancer Study Group of Japan, "Primary liver cancer in Japan. Sixth report", Cancer, 60, pp.1400~1411 (1987)
- Liver Cancer Study Group of Japan, "Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment", Ann Surg, 211, pp.277~287 (1990)
- Wheeler PG, "Non-operative arterial embolisation in primary liver tumours", Br Med J, 2, pp.242~244 (1979)
- Chuang VP, "Hepatic artery embolization in the treatment of hepatic neoplasms", Radiology, 140, pp.51~58 (1981)
- Okamura J, "An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies", World J Surg, 6, pp.352~357 (1982)
- Yamada R, "Hepatic artery embolization in 120 patients with unresectable hepatoma", Radiology, 148, pp.397~401 (1983)
- Lin DY, "Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial", Gastroenterology, 94, pp.453~456 (1988)
- Ikeda K, "Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model", Cancer, 68, pp.2150~2154 (1991)
- Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
- Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
- Shibata J, "Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma", Cancer, 64, pp.1586~1594 (1989)
- Sasaki Y, "A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge", Cancer, 60, pp.1194~1203 (1987)
- Imaoka S, "A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma", Cancer Chemother Pharmacol, (23 Suppl), pp.S126~S128 (1989)
- Yamamoto K, "Intraarterial infusion chemotherapy with lipiodol-CDDP suspension for hepatocellular carcinoma", Cardiovasc Intervent Radiol, 23, pp.26~39 (2000)
- Maeda S, "Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma", Hepatogastroenterology, 50, pp.809~813 (2003)
- Ikeda M, "Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma", Oncology, 66, pp.24~31 (2004)
- Ando E, "Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases", Cancer, 95, pp.588~595 (2002)
- Kaneko S, "Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis", Oncology, (62 Suppl 1), pp.69~73 (2002)
- Kawamura Y, "Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin", Hepatol Res, 39, pp.346~354 (2009)
- Yamaoka K, "Automated pharmacokinetic analysis system" (1984), Nankodo
- "Stable lipiodolized emulsions for hepatoma targeting and treatment by transcatheter arterial chemoembolization", Journal of controlled release : official journal of the Controlled Release Society, 50, pp.135~143 (1998), Elsevier Science Publishers
- Demachi H, "Simulation model based on non-newtonian fluid mechanics applied to the evaluation of the embolic effect of emulsions of iodized oil and anticancer drug", Cardiovasc Intervent Radiol, 23, pp.285~290 (2000)
- Morimoto K, "Transarterial chemoembolization using cisplatin powder in a rabbit model of liver cancer", Cardiovasc Intervent Radiol, 31, pp.981~985 (2008)
- Kawaoka T, "Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma", J Vasc Interv Radiol, 21, pp.1219~1225 (2010)
- Varela M, "Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics", J Hepatol, 46, pp.474~481 (2007)
- Hong K, "New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer", Clin Cancer Res, 12, pp.2563~2567 (2006)
- Lewis AL, "DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization", J Vasc Interv Radiol, 17(2 Pt 1), pp.335~342 (2006)
- Jordan O, "Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan", J Vasc Interv Radiol, 21, pp.1084~1090 (2010)
- Maeda N, "In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization", J Vasc Interv Radiol, 21, pp.877~881 (2010)
- Seki A, "Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma", Cardiovasc Intervent Radiol, 35, pp.555~562 (2012)